Shares of Savara Inc (NASDAQ:SVRA – Get Free Report) gapped down before the market opened on Wednesday after HC Wainwright lowered their price target on the stock from $10.00 to $6.00. The stock had previously closed at $3.83, but opened at $3.67. HC Wainwright currently has a buy rating on the stock. Savara shares last traded at $3.61, with a volume of 493,595 shares traded.
Several other analysts have also recently commented on SVRA. JMP Securities restated a “market outperform” rating and set a $9.00 price target on shares of Savara in a report on Tuesday, October 1st. Evercore ISI reaffirmed an “in-line” rating and set a $5.00 price objective (down previously from $7.00) on shares of Savara in a research report on Wednesday. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, Savara currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.17.
Check Out Our Latest Stock Report on SVRA
Hedge Funds Weigh In On Savara
Savara Price Performance
The stock has a fifty day moving average of $3.97 and a 200-day moving average of $4.22. The company has a quick ratio of 11.31, a current ratio of 11.31 and a debt-to-equity ratio of 0.26. The firm has a market capitalization of $584.33 million, a P/E ratio of -8.45 and a beta of 1.02.
Savara (NASDAQ:SVRA – Get Free Report) last released its earnings results on Monday, August 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). Equities analysts predict that Savara Inc will post -0.44 EPS for the current fiscal year.
About Savara
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Featured Articles
- Five stocks we like better than Savara
- The Most Important Warren Buffett Stock for Investors: His Own
- SoundHound AI Will Advance By Triple Digits in 2025: Here’s Why
- Upcoming IPO Stock Lockup Period, Explained
- Celsius Holdings: Big Drop, Big Opportunity? Analysts Say Yes
- How to Read Stock Charts for Beginners
- Is Palantir’s AI Edge Enough to Justify Its Price?
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.